MLYS (STOCKS)
Mineralys Therapeutics, Inc. Common Stock
$26.090000
-0.960000 (-3.55%)
Prev close: $27.050000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Jon Congleton
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $2,420.16M
- Employees
- 51
- P/E (TTM)
- -6.37
- P/B (TTM)
- 4.34
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
5
Strong Buy
9
Buy
2
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Jun 2026 (Q2)
|
$-2.85 | $-0.55 | -2.3043 | -422.27% |
|
Mar 2026 (Q1)
|
$-0.47 | $-0.47 | +0.0005 | +0.11% |
|
Dec 2025 (Q4)
|
$-0.40 | $-0.54 | +0.1435 | +26.40% |
|
Sep 2025 (Q3)
|
$-0.52 | $-0.63 | +0.1124 | +17.77% |
Financial Statements
| Revenues | $0.00 |
| Nonoperating Income/Loss | $21.22M |
| Operating Expenses | $370.79M |
| Research and Development | $301.59M |
| Other Operating Expenses | $69.20M |
| Operating Income/Loss | -$370.79M |
| Income/Loss From Continuing Operations After Tax | -$349.58M |
| Income/Loss From Continuing Operations Before Tax | -$349.58M |
| Net Income/Loss | -$349.58M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$349.58M |
| Net Income/Loss Available To Common Stockholders, Basic | -$349.58M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$4.19 |
| Diluted Earnings Per Share | -$4.19 |
| Basic Average Shares | 242,679,259 |
| Diluted Average Shares | 242,679,259 |
| Assets | $667.85M |
| Current Assets | $665.80M |
| Noncurrent Assets | $2.05M |
| Fixed Assets | $27.00K |
| Other Non-current Assets | $2.02M |
| Liabilities | $116.94M |
| Current Liabilities | $19.32M |
| Accounts Payable | $1.07M |
| Other Current Liabilities | $18.25M |
| Noncurrent Liabilities | $97.62M |
| Long-term Debt | $100.00K |
| Other Non-current Liabilities | $97.52M |
| Equity | $550.92M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $550.92M |
| Liabilities And Equity | $667.85M |
| Net Cash Flow From Operating Activities | -$138.79M |
| Net Cash Flow From Operating Activities, Continuing | -$138.79M |
| Net Cash Flow From Investing Activities | -$484.16M |
| Net Cash Flow From Investing Activities, Continuing | -$484.16M |
| Net Cash Flow From Financing Activities | $659.43M |
| Net Cash Flow From Financing Activities, Continuing | $659.43M |
| Net Cash Flow | $36.48M |
| Net Cash Flow, Continuing | $36.48M |
| Comprehensive Income/Loss | -$349.58M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$349.58M |
| Other Comprehensive Income/Loss | $0.00 |